<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-PHTV9K7" height="0" width="0" style="display:none;visibility:hidden">
Loading
Skip to Main Content
Product cover image for Tenomix: Scaling an Artificial Intelligence-Powered Cancer Solution

Tenomix: Scaling an Artificial Intelligence-Powered Cancer Solution

Gantous, Alexis; Mostafa, Romel

Product #:W47986
Supplier:Ivey
Discipline:Entrepreneurship
Setting:Canada;North America, 2025
Details:Case (PDF) • 11 pages • 2026-02-12 (Rev: 2026-04-30)

Subjects:

EntrepreneurshipStrategyEntrepreneurshipStrategy

Industries:

Healthcare sectorHealthcare sector

Geography:

CanadaNorth AmericaCanada
Your Price:$10.54

Purchase this material with a free Educator Account and enjoy more benefits:

  • Free Educator Copy
  • Free Teaching Notes
  • Build your coursepack
  • Discounted academic price

Tenomix Inc., a Canadian medical technology startup, developed the Lymphonator—a semi-automated device that used robotics, ultrasound imaging, and artificial intelligence (AI) to identify lymph nodes in colorectal cancer specimens. After securing early funding and prototype validation with hospitals, the chief executive officer, Saumik Biswas, must choose a go-to-market model to scale: flat-rate pricing, perpetual licensing, or subscription. His decision will shape Tenomix’s valuation, investor confidence, hospital adoption, and the company’s ability to expand into new cancer applications while navigating evolving AI and data-privacy regulations.

Learning Objectives

This case is well-suited for senior undergraduate, graduate, or executive-level courses in entrepreneurship, finance, innovation management, or strategy. It is an integrative case that also offers an opportunity to incorporate financial analysis. After working through the case and assignment questions, students should be able to do the following:

  • Understand how business model selection shapes valuation, customer relationships, data access, and the scalability of AI-enabled cancer-detection technologies.
  • Identify regulatory, procurement, and data-governance barriers affecting adoption of AI-driven medical devices.
  • Apply discounted cash flow analysis to compare commercialization pathways and assess key financial trade-offs (optional).
  • Recommend go-to-market strategies that balance fiscal sustainability with clinical effect and long-term growth.
Loading
Case Study: Tenomix: Scaling an Artificial Intelligence-Powered Cancer Solution (English version) | Ivey Publishing